ARCT - Arcturus Therapeutics Holdings Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5142.99M
Enterprise Value 3115.78M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)5.61
Price/Book (mrq)6.61
Enterprise Value/Revenue 34.54
Enterprise Value/EBITDA 6-10.09

Trading Information

Stock Price History

Beta (3Y Monthly) 3.20
52-Week Change 334.90%
S&P500 52-Week Change 30.90%
52 Week High 315.50
52 Week Low 34.11
50-Day Moving Average 310.53
200-Day Moving Average 37.62

Share Statistics

Avg Vol (3 month) 388.31k
Avg Vol (10 day) 386.57k
Shares Outstanding 510.72M
Float 8.44M
% Held by Insiders 146.92%
% Held by Institutions 114.51%
Shares Short (Jul 31, 2019) 466.07k
Short Ratio (Jul 31, 2019) 40.76
Short % of Float (Jul 31, 2019) 40.81%
Short % of Shares Outstanding (Jul 31, 2019) 40.50%
Shares Short (prior month Jun 28, 2019) 489.68k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 27/1
Last Split Date 3Nov 16, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -50.32%
Operating Margin (ttm)-47.63%

Management Effectiveness

Return on Assets (ttm)-13.17%
Return on Equity (ttm)-65.12%

Income Statement

Revenue (ttm)25.5M
Revenue Per Share (ttm)2.51
Quarterly Revenue Growth (yoy)325.50%
Gross Profit (ttm)-1.23M
EBITDA -11.47M
Net Income Avi to Common (ttm)-12.83M
Diluted EPS (ttm)-1.26
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)55.84M
Total Cash Per Share (mrq)3.91
Total Debt (mrq)16.03M
Total Debt/Equity (mrq)74.16
Current Ratio (mrq)3.86
Book Value Per Share (mrq)1.65

Cash Flow Statement

Operating Cash Flow (ttm)-8.63M
Levered Free Cash Flow (ttm)-14.06M